Improved Quality of Life upon Shifting from Darbepoetin to Luspatercept in Patients with Low-Risk Myelodysplastic Syndrome (MDS)

被引：0
|
作者：
Almomen, Abdulkareem Mohammed [1 ,2 ]
Dwaima, Mohammed Eid [2 ]
Akkad, Hadeel Bashir [2 ]
Owaidah, Tarek M. [2 ]
机构：
[1] King Saud Univ, King Khalid Univ Hosp, Med, Riyadh, Saudi Arabia
[2] Natl Blood & Canc Ctr, Riyadh, Saudi Arabia
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178190
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [1] Baseline predictors of response to treatment with darbepoetin-alpha (DA) in anemic patients with low-risk myelodysplastic syndrome (MDS)
    Gabrilove, J.
    Paquette, R.
    Lyons, R.
    Mushtaq, C.
    Sekeres, M.
    Tomita, D.
    Lillie, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Treatment of myelodysplastic syndrome (MDS) with cytokine immunotherapy for low-risk MDS
    Kadia, Tapan M.
    Kantadian, Hagop
    Verstovsek, Srdan
    Newman, Beth
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    BLOOD, 2007, 110 (11) : 438A - 438A
  • [3] Efficacy of Luspatercept in Low-Risk Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
    Amitai, Irina
    Gurion, Ronit
    Raanani, Pia
    Yeshurun, Moshe
    Wolach, Ofir
    Merkel, Drorit
    Amitai, Yoav
    Gafter-Gvili, Anat
    Shargian, Liat
    BLOOD, 2023, 142
  • [4] SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPENDENCE REFRACTORY TO ERYTHROPOIETIN THERAPY
    Jonasova, A.
    Minarik, L.
    Stopka, T.
    Sotakova, S.
    Polackova, H.
    Zemanova, Z.
    LEUKEMIA RESEARCH, 2023, 128
  • [5] Quality of Life in Low-Risk MDS: An Undervalued Endpoint
    Heyrman, Bert
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (19)
  • [6] Quality of Life in Low-Risk Myelodysplastic Syndrome: A Cross-Sectional Study
    Kaygusuz-Atagunduz, Isik
    Ozen, Mirac
    Firatli-Tuglular, Tulin
    Toptas, Tayfur
    BLOOD, 2015, 126 (23)
  • [7] First Single-Center Experience with Luspatercept Therapy in Low-Risk Myelodysplastic Syndrome (LR-MDS) Patients with Transfusion Dependence Refractory to Erythropoietin Therapy
    Jonasova, Anna
    Minarik, Lubomir
    Zemanova, Zuzana
    Polackova, Helena
    Stopka, Tomas
    BLOOD, 2022, 140 : 12311 - 12312
  • [8] Immunomodulatory cytokines and clonal dynamics in low-risk myelodysplastic syndromes patients treated with luspatercept
    Fattizzo, Bruno
    Marchetti, Alfredo
    Zaninoni, Anna
    Lionetti, Marta
    Riva, Marta
    Rizzo, Lorenzo
    Pettine, Loredana
    Galli, Nicole
    Mazzon, Federico
    Fermo, Elisa
    Maeda, Akihiro
    Marella, Alessio
    Da Via, Matteo Claudio
    Passamonti, Francesco
    Bolli, Niccolo
    Barcellini, Wilma
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : E345 - E348
  • [9] Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
    Shamis Khan
    Sara Taveras Alam
    Rosa Torres Ramos
    John Etumbani Mbue
    Effrosyni Apostolidou
    Gustavo A. Rivero
    Sarvari Venkata Yellapragada
    Clinical Hematology International, 2022, 4 (4) : 148 - 151
  • [10] The role of rHuEpo in low-risk myelodysplastic syndrome patients
    Rigolin, GM
    Castoldi, G
    LEUKEMIA & LYMPHOMA, 2005, 46 (06) : 823 - 831
12345